Lüker Jakob, Sultan Arian, Sehner Susanne, Hoffmann Boris, Servatius Helge, Willems Stephan, Steven Daniel
Department of Electrophysiology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
University Hospital Eppendorf, Martinistrasse 52, 20249, Hamburg, Germany.
Heart Vessels. 2016 Oct;31(10):1669-75. doi: 10.1007/s00380-015-0771-0. Epub 2015 Nov 6.
Catheter ablation of complex fractionated atrial electrograms (CFAE), also known as defragmentation ablation, may be considered for the treatment of persistent atrial fibrillation (AF) beyond pulmonary vein isolation (PVI). Concomitant antiarrhythmic drug (AAD) therapy is common, but the relevance of AAD administration and its optimal timing during ablation remain unclear. Therefore, we investigated the use and timing of AADs during defragmentation ablation and their possible implications for AF termination and ablation success in a large cohort of patients. Retrospectively, we included 200 consecutive patients (age: 61 ± 12 years, LA diameter: 47 ± 8 mm) with persistent AF (episode duration 47 ± 72 weeks) who underwent de novo ablation including CFAE ablation. In all patients, PVI was performed prior to CFAE ablation. The use and timing of AADs were registered. The follow-ups consisted of Holter ECGs and clinical visits. Termination of AF was achieved in 132 patients (66 %). Intraprocedural AADs were administered in 168/200 patients (84 %) 45 ± 27 min after completion of PVI. Amiodarone was used in the majority of the patients (160/168). The timing of AAD administration was predicted by the atrial fibrillation cycle length (AFCL). At follow-up, 88 patients (46 %) were free from atrial arrhythmia. Multivariate logistic regression analysis revealed that administration of AAD early after PVI, LA size, duration of AF history, sex and AFCL were predictors of AF termination. The administration of AAD and its timing were not predictive of outcome, and age was the sole independent predictor of AF recurrence. The administration of AAD during ablation was common in this large cohort of persistent AF patients. The choice to administer AAD therapy and the timing of the administration during ablation were influenced by AFCL, and these factors did not significantly influence the moderate single procedure success rate in this retrospective analysis.
对于持续性心房颤动(AF),除肺静脉隔离(PVI)外,可考虑采用导管消融复杂碎裂心房电图(CFAE),也称为去碎片化消融。抗心律失常药物(AAD)联合治疗很常见,但AAD给药的相关性及其在消融过程中的最佳时机仍不明确。因此,我们在一大群患者中研究了去碎片化消融过程中AAD的使用和时机及其对AF终止和消融成功的可能影响。回顾性研究中,我们纳入了200例连续的持续性AF患者(年龄:61±12岁,左房直径:47±8mm,发作持续时间47±72周),他们接受了包括CFAE消融在内的初次消融。所有患者在CFAE消融前均进行了PVI。记录了AAD的使用和时机。随访包括动态心电图和临床就诊。132例患者(66%)实现了AF终止。168/200例患者(84%)在PVI完成后45±27分钟接受了术中AAD治疗。大多数患者使用了胺碘酮(160/168)。AAD给药时机由房颤周期长度(AFCL)预测。随访时,88例患者(46%)无房性心律失常。多因素逻辑回归分析显示,PVI后早期给予AAD、左房大小、AF病史持续时间、性别和AFCL是AF终止的预测因素。AAD的给药及其时机不能预测结局,年龄是AF复发的唯一独立预测因素。在这一大群持续性AF患者中,消融期间给予AAD很常见。在消融期间给予AAD治疗的选择和给药时机受AFCL影响,在这项回顾性分析中,这些因素并未显著影响中等的单次手术成功率。